NCT07156929View on ClinicalTrials.gov

Kinetics and Metabolism of Nicotinamide Provided as a Dietary Supplementation

NACompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

April 20, 2024

Primary Completion Date

May 20, 2025

Study Completion Date

June 30, 2025

Conditions
Respiratory Infection (for Example, Pneumonia, Bronchitis)Respiratory Infection VirusCommunity Acquired Pneumonia (CAP)COPD Acute ExacerbationInflammatory Bowel Disease (IBD)
Interventions
DIETARY_SUPPLEMENT

Controlled-ileocolonic-release nicotinamide (CICR-NAM): 500 mg/d

Controlled-ileocolonic-release nicotinamide (CICR-NAM) film-coated tablets release 500 mg nicotinamide per tablet at a pH of 7, leading to a delayed and prolonged systemic exposure to nicotinamide and to exposure of the ileum and colon including the gut microbiome.

DIETARY_SUPPLEMENT

Controlled-ileocolonic-release nicotinamide (CICR-NAM): 1000 mg/d

Controlled-ileocolonic-release nicotinamide (CICR-NAM) film-coated tablets release 500 mg nicotinamide per tablet at a pH of 7, leading to a delayed and prolonged systemic exposure to nicotinamide and to exposure of the ileum and colon including the gut microbiome.

Trial Locations (1)

24105

University Hospital Schleswig-Holstein, Campus Kiel, Kiel

All Listed Sponsors
lead

University Hospital Schleswig-Holstein

OTHER

NCT07156929 - Kinetics and Metabolism of Nicotinamide Provided as a Dietary Supplementation | Biotech Hunter | Biotech Hunter